Imaging Biometrics

Dr. Max Krucoff’s use of Delta T1 maps to assess ablation extent after LITT is a powerful example of how the objective, quantitative imaging of Delta T1 maps can elevate clinical decision-making and confidence.

Unlike conventional image (like T1+C) that rely on subjective interpretation, Delta T1 maps remove ambiguity—delivering reproducible insights that support better outcomes.

Proud to see Imaging Biometrics’ technology helping clinicians push the boundaries of neuro-oncology!

x.com

We're looking forward to this upcoming event with industry leaders!

Glioblastoma Drug Development Summit | March 2024 Implementing Diverse Mechanisms Across Improved Clinical Translation to Develop Safe, Effective & Deliverable Glioblastoma Therapies

While a small study, advanced imaging proves important to Tumor Treating Fields.

NIMG-29. ADVANCED MRI BIOMARKERS PREDICT EARLY RESPONSE TO TUMOR TREATING FIELDS IN GLIOBLASTOMA AbstractBACKGROUND. Tumor-treating fields (TTFields) is a novel US FDA-approved antimitotic treatment modality for patients with newly diagnosed and recurrent g

Here's a good research article describing the effects of Gallium Maltolate, for more information about the Expanded Access Program, or to sign up please fill out the form on our website:

Contact Us – Clinical Trials Expanded Access Program – Imaging Biometrics